Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
Summary
Treace Medical Concepts reported mixed Q4 and full-year 2025 results, but issued a notably negative outlook for 2026. While full-year 2025 revenue grew 2% to $212.7 million and adjusted EBITDA loss improved, Q4 revenue declined 9% year-over-year to $62.5 million, and net loss significantly widened to $(9.4) million. Crucially, the company's 2026 guidance projects a revenue decline of 0% to 6% compared to 2025, and an increased Adjusted EBITDA loss of $4.0 million to $6.0 million. This negative forward guidance, driven by a shift towards lower-priced products, is a material concern for this small-cap medical technology company and suggests continued operational headwinds. Traders will be watching for signs of the projected topline growth restoration in the second half of 2026.
At the time of this announcement, TMCI was trading at $2.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.8M. The 52-week trading range was $1.81 to $10.03. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.